Tag: Health Care

Displaying 621 - 640 of 992 results.

Pages

The Federal Trade Commission today announced its decision to challenge Barr Pharmaceutical, Inc.’s proposed acquisition of Pliva d.d for approximately $2.5 billion. The FTC’s complaint alleges that the acquisition as originally structured would have eliminated current or future competition between...
The Federal Trade Commission today charged that Thermo Electron Corporation’s proposed $12.8 billion acquisition of Fisher Scientific International, Inc. would harm competition in the U.S. market for high-performance centrifugal vacuum evaporators (CVEs) in violation of the antitrust laws.
The consent order settled charges that Thermo Electron Corporation’s proposed $12.8 billion acquisition of Fisher Scientific International, Inc. would harm competition in the U.S. market for high-performance centrifugal vacuum evaporators (CVEs). Thermo and Fisher are the only two...
Commission approval of staff comments to the Virginia House of Delegates: The FTC has approved the filing of comments by the staffs of the Bureaus of Competition and Economics and the Office of Policy Planning with the Virginia House of Delegates on the subject of pharmacy benefit managers (PBMs...
The Federal Trade Commission today told the Senate Judiciary Committee that the agency protects health care consumers from anti-competitive conduct by enforcing antitrust laws, and that the FTC is committed to working with physicians and other providers to give them guidance to avoid antitrust...
The Commission approved a final consent order settling Commission charges alleging that two independent practice associations (IPAs) and 18 member physician practices in the Kansas City, MO area, refused to deal with health care plans, except on collectively agreed-upon prices and...
The Federal Trade Commission today announced its decision to challenge the conduct of two independent practice associations (IPAs) and 18 member physician practices in the Kansas City area for refusing to deal with health care plans, except on collectively agreed-upon terms, including price. The...
The Commission approved a final consent order settling charges alleging that thirty competing association members acted unlawfully by agreeing to set the prices they would charge dental insurance plans, and by refusing to deal with plans that would not accept the collectively...
The Commission approved a final consent order to ensure the maintenance of competition in the market for prone stereotactic breast biopsy systems (SBBSs). The Commission had challenged this merger which was consummated in 2005. The order required the divestiture of all prone SBBS...
Commission approval of final consent order: Following a public comment period, the FTC has approved the issuance of a final consent order in the matter concerning Fresenius AG and Renal Care Group. The Commission vote to issue the final order was 5-0. Copies are available now on the FTC’s Web site...
Staff issues advisory opinion concerning Non-Profit Institutions Act: The staff of the Bureau of Competition has advised Alpena (Michigan) Public Schools that its proposed plan to have pharmaceuticals transferred to it for use by its employees, by the Alpena Regional Medical Center, with actual...
Commission approval of proposed divestitures: The Commission has granted a petition from DaVita Inc. (DaVita) requesting approval of a proposed divestiture related to its recent acquisition of Gambro Healthcare (Gambro). Under the consent order, issued to resolve the competitive problems in the...
The Federal Trade Commission’s Bureau of Competition today issued a summary of agreements filed with the Commission in fiscal year 2005 (ending September 30, 2005) by generic and branded drug manufacturers. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 requires drug...
Commission approval of final consent order: Following a public comment period, the Commission has approved the issuance of a final consent order in the matter concerning Allergan, Inc.’s acquisition of Inamed Corporation. The vote to approve the final order was 4-0, with Commissioner J. Thomas...
The consent order settles chargers that the $27 billion acquisition of Guidant Corporation by Boston Scientific Corporation would harm competition and consumers in several significant medical device markets. Guidant Corporation by Boston Scientific Corporation are the largest market...
Fresenius AG will sell 91 outpatient kidney dialysis clinics and financial interests in 12 more to settle Federal Trade Commission charges that Fresenius’ purchase of rival dialysis provider Renal Care Group, Inc. would violate federal antitrust laws. When the deal is finalized, Fresenius will be...
The Federal Trade Commission today announced its intention to conduct a study of the use, and likely short- and long-term competitive effects, of authorized generics in the prescription drug marketplace. An authorized generic is chemically identical to a particular brand-name drug, but the brand-...
A proposed plan by a physician-hospital organization that would involve collective bargaining with insurers over doctor fees likely would violate federal antitrust laws, according to the FTC staff. The staff concluded that the price and other competitive restraints proposed by the network were not...
Botox marketer Allergan, Inc., and the Inamed Corporation will divest the rights to develop and distribute Reloxin, a potential Botox rival, to settle Federal Trade Commission charges that Allergan’s $3.2 billion purchase of Inamed would violate federal antitrust laws. The FTC alleges that...

Pages